Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CXCL9 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CXCL9 ECD-Fc / His-tag Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CXCL9 Products |
| Gene Delivery | CXCL9 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. High-titer transduction. |
View CXCL9 Products |
| Benchmark Ab | Anti-CXCL9 Recombinant Antibody Recombinant positive control derived from clinical-stage sequences. |
View CXCL9 Products |
| Validator | CXCL9 siRNA Set For knockdown verification and specificity validation. |
View CXCL9 Products |
| Related Target A | CXCR3 The primary G-protein coupled receptor (GPCR) for CXCL9. Essential for chemotaxis assays. |
View CXCR3 Products |
| Related Target B | CXCL10 Synergistic CXCR3 ligand. Crucial for cross-reactivity and selectivity screening. |
View CXCL10 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heparin-Binding Non-Specific Interference | High Purity (>95% by SDS-PAGE) and Theoretical MW verification to ensure clean baseline in binding assays. |
| Receptive GPCR Cell Line Construction (CXCR3) | Lentivirus Premade Particles for stable, high-density CXCR3 expression, bypassing VLP stability issues. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay window calibration. |
| False Positives | Sequence-verified siRNA sets included for target-specific knockdown validation. |
Live CXCL9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CXCL9 therapeutics is intensifying, with major players shifting focus from traditional mAbs to combination therapies and biomarker-driven patient selection. In immuno-oncology, CXCL9 serves as a critical "hot tumor" biomarker, where therapeutic strategies focus on inducing its expression to recruit CXCR3+ T cells and NK cells into the tumor microenvironment. Conversely, in autoimmune disorders such as vitiligo, alopecia areata, and graft-versus-host disease (GVHD), blocking the CXCL9/CXCR3 axis is the dominant therapeutic trend.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing mAb | Amgen, Pfizer | Vitiligo, Alopecia Areata, GVHD | Ligand-receptor blocking assay (Requires high-purity CXCL9 and CXCR3 stable cell lines) |
| Small Molecule (CXCR3 Antagonist) | GlaxoSmithKline, Actelion | Psoriasis, Inflammatory Bowel Disease | Competitive binding assays (Requires sequence-verified CXCL9 protein and receptor-expressing lentiviruses) |
| mRNA / Vector (Inducer) | BioNTech, Moderna | Cold Solid Tumors (combination with PD-1) | Expression validation and functional chemotaxis (Requires native glycosylated CXCL9 as standard) |